Mark Fitzgerald, MB, MCh, BAO, MD, FRCPI, FRCPC, FACCP, FACP
Professor and Head, Respiratory Medicine, UBC
Dr. J. Mark FitzGerald graduated from University College Dublin in 1978. After interning and training in Internal Medicine in Dublin, he worked for two years in Lesotho, Southern Africa as a General Internist. Subsequently, he completed post-graduate training in Respiratory Medicine and Clinical Epidemiology at McMaster University before accepting a position on faculty at McMaster University in 1987. In 1989, he moved to the University of British Columbia, he currently is based at The Lung Centre at Vancouver General Hospital and is also a Senior Scientist at the Centre for Clinical Epidemiology and Evaluation at the Vancouver Coastal Health Research Institute. Dr. FitzGerald is Head of the Respiratory Medicine Divisions at both UBC and Vancouver General Hospital and co -Director of the UBC Institute for Heart and Lung Health. His clinical and research interests include asthma, chronic obstructive lung disease, tuberculosis, and health outcomes. His current research focuses on health literacy and ethnicity in the management of asthma and COPD as well as the economic evaluation of asthma and its cost effective treatment. He has been involved in a number of regional and provincial initiatives to improve COPD care. As a PI with the NCE AllerGen, he is involved in the evaluation of novel new asthma therapies. He is past Chair of the GINA Science Committee and current Chair of the GINA Executive. He is President Elect of the Canadian Thoracic Society. He has published over 320 peer reviewed papers and editorials in high impact journals including: the New England Journal of Medicine, British Medical Journal, The Lancet, Annals of Internal Medicine and the Journal of the American Medical Association.
- Chronic cough
Dr Stirling Bryan is a trained economist with a career-long specialization in the economics of health care. His PhD (Economics) was obtained from Brunel University (UK), following a Masters (Health Economics) from the University of York (UK). For over 20 years he has been a university-based practicing health economist with extensive engagement to the policy and decision making world. The vast majority of his career has been spent in the UK, initially in London (appointments at St Thomas’ Hospital Medical School and then Brunel University) and subsequently in Birmingham (senior lecturer and then full professor at the University of Birmingham). He has taught health economics to undergraduate economists and medical trainees, to postgraduate health economics students and to health sector professionals. His research track record reveals a longstanding goal of informing policy and practice. This is demonstrated, in part, through an extensive involvement with the UK National Institute for Health & Clinical Excellence (NICE). For many years he led the University of Birmingham team that conducted economic analyses for NICE, and subsequently served for 3 years as a member of the NICE technology appraisals committee, advising on coverage policy. In 2005 he was awarded a Commonwealth Fund Harkness Fellowship and spent one year in the US, based at Stanford University, researching technology coverage decision making in a US health care organisations. His published papers reveal an ongoing research interest in coverage decision making processes. Since his relocation to Canada in 2008 (appointment as full professor in UBC’s School of Population & Public Health, and Director of the Centre for Clinical Epidemiology & Evaluation, VCH Research Institute), he has continued a focus on policy-relevant research. His current position, sponsored by Vancouver Coastal Health, sees him working alongside policy colleagues in one of BC’s largest regional health authorities.
Larry Lynd, B.S.P., Ph.D.
Director, Collaboration for Outcomes Research and Evaluation (CORE)
Professor, Faculty of Pharmaceutical Sciences, UBC
Larry received his B.S.P. in 1986 from the University of Saskatchewan and his Ph.D. in the Department of Health Care and Epidemiology at the University of British Columbia in 2002. He then completed a 2-year post-doctoral fellowship in health economics with Dr. Bernie O’Brien at McMaster University. He is a Professor in the Faculty of Pharmaceutical Sciences and is the Director of CORE. He is a Scientist at the Centre for Clinical Epidemiology and Evaluation; Scientist at the Centre for Health Evaluation and Outcomes Sciences; Scholar at the Peter Wall Institute of Advanced Studies; and Associate of the School of Population and Public Health. He was a Michael Smith Foundation for Health Research Scholar and a Canadian Institutes of Health Research New Investigator.
Dr. Lynd has made significant service contributions, serving on a number of committees, including Chair of the Health Canada Special Advisory Committee on Non-prescription drugs; Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada; BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee; and the BC PharmaNet Data Stewardship Committee.
His primary areas of scholarly interest are in the conduct of state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis using state-of-the-art computer simulation modeling, measurement of health related quality of life and patient’s preferences, and pharmacoepidemiology. One of his primary research objectives is to be involved specifically in research that will ultimate translate into improved patient outcomes, or be integrated into the decision-making process.
- Pharmaceutical outcomes research
- Risk-benefit analysis methods
- Asthma-related outcomes
- Population health and socioeconomic differences in prescribing and disease management
- Database analysis
- Longitudinal analysis